Evidence map›Paper›PMID 42152606›Full record

ArticleThe journal of obstetrics and gynaecology research2026

Long-Term Disease-Free Survival After Systemic-First Sequential Multimodal Therapy for Advanced and Recurrent Large-Cell Neuroendocrine Carcinoma of the Uterine Cervix: A Case Report.

Kimio Wakana, Mayu Akita, Fumiko Tsubata, Yusuke Kori, Tamami Odai, Naoyuki Miyasaka

Abstract readCase Reports
In one paragraph

Article in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kimio WakanaDepartment of Obstetrics and Gynecology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0008-0874-8888
Mayu AkitaDepartment of Obstetrics and Gynecology, Institute of Science Tokyo, Tokyo, Japan.
Fumiko TsubataDepartment of Obstetrics and Gynecology, Institute of Science Tokyo, Tokyo, Japan.
Yusuke KoriDepartment of Perinatal and Maternal Medicine (Ibaraki), Institute of Science Tokyo, Tokyo, Japan.
Tamami OdaiDepartment of Women's Health, Institute of Science Tokyo, Tokyo, Japan.
Naoyuki MiyasakaDepartment of Obstetrics and Gynecology, Institute of Science Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical large-cell neuroendocrine carcinoma (LCNEC) is a rare and highly aggressive malignancy with poor prognoses, particularly in advanced or recurrent disease. We describe a case of advanced and recurrent cervical LCNEC in which long-term disease-free survival was achieved following a systemic-first, sequential multimodal treatment strategy. A 41-year-old woman presented with abnormal vaginal bleeding and was diagnosed with cervical LCNEC with pelvic and para-aortic lymph node metastases. Neoadjuvant irinotecan-cisplatin chemotherapy resulted in marked tumor regression, enabling radical hysterectomy. Postoperative therapy consisted of etoposide-cisplatin chemotherapy, followed by pelvic and para-aortic radiotherapy. Mediastinal lymph node recurrence developed 3 years later and was successfully treated using the same chemotherapy regimen combined with site-directed radiotherapy, resulting in complete remission. The patient remained disease-free 9 years after the final treatment completion. This case suggests that carefully sequenced systemic chemotherapy, surgery, and radiotherapy integration may provide durable disease control in selected patients with advanced or recurrent cervical LCNEC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Large CellCarcinoma, NeuroendocrineNeoplasm Recurrence, LocalUterine Cervical NeoplasmsAdultCisplatinCombined Modality TherapyDisease-Free SurvivalFemaleHumansCisplatincervical cancerchemoradiotherapylarge celllymph node metastasesneuroendocrine carcinoma

Identifiers

PMID42152606
PMCPMC13184578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.